Andrea L. Kasinski

Department of Biological Sciences, Purdue University

Research Area

Biography

Andrea L. Kasinski has not added Biography.
If you are Andrea L. Kasinski and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2023

Other Publications

Article	Year
Aberrant regulation and function of microRNAs in cancer. Current biology : CB\| PubMed ID: 25137592	2014
A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene\| PubMed ID: 25174400	2015
RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes. Journal of hematology & oncology\| PubMed ID: 25888285	2015
MicroRNAs in Cancer: A Historical Perspective on the Path from Discovery to Therapy. Cancers\| PubMed ID: 26226002	2015
Targeting adhesion signaling in mutant lung adenocarcinoma. JCI insight\| PubMed ID: 28289710	2017
Sulforhodamine B (SRB) Assay in Cell Culture to Investigate Cell Proliferation. Bio-protocol\| PubMed ID: 28573164	2016
FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer. Science translational medicine\| PubMed ID: 28768807	2017
Animal Models to Study MicroRNA Function. Advances in cancer research\| PubMed ID: 28882225	2017
No vehicle, no problem. Oncotarget\| PubMed ID: 29228541	2017
MicroRNA-223 Suppresses the Canonical NF-κB Pathway in Basal Keratinocytes to Dampen Neutrophilic Inflammation. Cell reports\| PubMed ID: 29444433	2018
New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K/H Exchange. Bioconjugate chemistry\| PubMed ID: 29446616	2018
Enhancing MicroRNA Activity through Increased Endosomal Release Mediated by Nigericin. Molecular therapy. Nucleic acids\| PubMed ID: 31071527	2019
Identification and validation of microRNAs that synergize with miR-34a - a basis for combinatorial microRNA therapeutics. Cell cycle (Georgetown, Tex.)\| PubMed ID: 31258013	2019
Combatting PDAC with two tumor-targeting small RNAs. Oncotarget\| PubMed ID: 31666921	2019
Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer. Biochemical pharmacology\| PubMed ID: 32681833	2021
InVivo Cancer-Based Functional Genomics. Trends in cancer\| PubMed ID: 32828714	2020
MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic. Frontiers in cell and developmental biology\| PubMed ID: 33763422	2021
Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases. NAR cancer\| PubMed ID: 34316717	2021
Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells. Scientific reports\| PubMed ID: 35046472	2022
Author Correction: Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells. Scientific reports\| PubMed ID: 35165361	2022
Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET. Cancer research\| PubMed ID: 35404406	2022
In-Cell Western Protocol for Semi-High-Throughput Screening of Single Clones. Bio-protocol\| PubMed ID: 36199701	2022
Emerging diversity in extracellular vesicles and their roles in cancer. Frontiers in oncology\| PubMed ID: 37397375	2023
A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy. Oncogene\| PubMed ID: 37666938	2023
Histone 4 lysine 20 tri-methylation: a key epigenetic regulator in chromatin structure and disease. Frontiers in genetics\| PubMed ID: 37671044	2023